Top

Published in:

01-12-2015 | Original Article

Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial

Authors: Kenichi Tanaka, Masaaki Nakayama, Makoto Kanno, Hiroshi Kimura, Kimio Watanabe, Yoshihiro Tani, Yoshimitsu Hayashi, Koichi Asahi, Hiroyuki Terawaki, Tsuyoshi Watanabe

Published in: Clinical and Experimental Nephrology | Issue 6/2015

Abstract

Background

Hyperuricemia is associated with the onset of chronic kidney disease (CKD) and renal disease progression. Febuxostat, a novel, non-purine, selective xanthine oxidase inhibitor, has been reported to have a stronger effect on hyperuricemia than conventional therapy with allopurinol. However, few data are available regarding the clinical effect of febuxostat in patients with CKD.

Methods

A prospective, randomized, open-label, parallel-group trial was conducted in hyperuricemic patients with stage 3 CKD. Patients were randomly assigned to treatment with febuxostat (n = 21) or to continue conventional therapy (n = 19). Treatment was continued for 12 weeks. The efficacy of febuxostat was determined by monitoring serum uric acid (UA) levels, blood pressures, renal function, and urinary protein levels. In addition, urinary liver-type fatty acid-binding protein (L-FABP), urinary albumin, urinary beta 2 microglobulin (β2MG), and serum high sensitivity C-reactive protein were measured before and 12 weeks after febuxostat was added to the treatment.

Results

Febuxostat resulted in a significantly greater reduction in serum UA (−2.2 mg/dL) than conventional therapy (−0.3 mg/dL, P < 0.001). Serum creatinine and estimated glomerular filtration rate changed little during the study period in each group. However, treatment with febuxostat for 12 weeks reduced the urinary levels of L-FABP, albumin, and β2MG, whereas the levels of these markers did not change in the control group.

Conclusion

Febuxostat reduced serum UA levels more effectively than conventional therapy and might have a renoprotective effect in hyperuricemic patients with CKD. Further studies should clarify whether febuxostat prevents the progression of renal disease and improves the prognosis of CKD.

Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56(6):2214–9. doi:10.1046/j.1523-1755.1999.00773.x.CrossRefPubMed

Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16–23.PubMed

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305. doi:10.1056/NEJMoa041031.CrossRefPubMed

Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–69. doi:10.1161/01.CIR.0000095676.90936.80.CrossRefPubMed

Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population–the Ohasama study. Nephrol Dial Transplant. 2007;22(7):1910–5. doi:10.1093/ndt/gfm051.CrossRefPubMed

Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642–50 [pii:S0272638604009345].CrossRefPubMed

Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239–47. doi:10.1053/j.ajkd.2007.05.013.CrossRefPubMed

Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19(6):1204–11. doi:10.1681/ASN.2007101075.PubMedCentralCrossRefPubMed

Kamei K, Konta T, Hirayama A, Suzuki K, Ichikawa K, Fujimoto S, et al. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant. 2014;. doi:10.1093/ndt/gfu256.

10.

Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796–803. doi:10.1053/j.ajkd.2008.12.021.PubMedCentralCrossRefPubMed

11.

Suliman ME, Johnson RJ, Garcia-Lopez E, Qureshi AR, Molinaei H, Carrero JJ, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 2006;48(5):761–71. doi:10.1053/j.ajkd.2006.08.019.CrossRefPubMed

12.

Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–21. doi:10.1056/NEJMra0800885.PubMedCentralCrossRefPubMed

13.

Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183–90. doi:10.1161/01.HYP.0000069700.62727.C5.CrossRefPubMed

14.

Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–93. doi:10.2215/CJN.01580210.PubMedCentralCrossRefPubMed

15.

Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47–56. doi:10.1016/0002-9343(84)90743-5.CrossRefPubMed

16.

Omori H, Kawada N, Inoue K, Ueda Y, Yamamoto R, Matsui I, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol. 2012;16(4):549–56. doi:10.1007/s10157-012-0609-3.CrossRefPubMed

17.

Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J. 2013;77(8):2043–9. doi:10.1253/circj.CJ-13-0082.CrossRefPubMed

18.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92. doi:10.1053/j.ajkd.2008.12.034.CrossRefPubMed

19.

Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. doi:10.1186/ar2978.PubMedCentralCrossRefPubMed

20.

Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010;56(2):264–72. doi:10.1053/j.ajkd.2010.01.019.CrossRefPubMed

21.

Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51–9. doi:10.1053/j.ajkd.2005.10.006.CrossRefPubMed

22.

Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013;125(1):106–14. doi:10.3810/pgm.2013.01.2626.CrossRefPubMed

23.

Tsuda H, Kawada N, Kaimori JY, Kitamura H, Moriyama T, Rakugi H, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427(2):266–72. doi:10.1016/j.bbrc.2012.09.032.CrossRefPubMed

24.

Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–32. doi:10.1001/jama.300.8.924.PubMedCentralCrossRefPubMed

25.

Agarwal V, Messerli F. Effect of allopurinol on blood pressure (author response to Allopurinol on hypertension: insufficient evidence to recommend). J Clin Hypertens (Greenwich). 2013;15(9):701. doi:10.1111/jch.12152.CrossRef

26.

Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res. 2014;37(10):919–25. doi:10.1038/hr.2014.107.CrossRefPubMed

27.

Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6.CrossRefPubMed

28.

Kobrin I, Frohlich ED, Ventura HO, Messerli FH. Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med. 1986;146(2):272–6.CrossRefPubMed

29.

Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739–42. doi:10.1111/j.1523-1755.2005.00273.x.CrossRefPubMed

30.

Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269–75. doi:10.1097/HJH.0b013e3282f240bf.CrossRefPubMed

31.

Povoa H Jr, Sa LD, Lessa VM. Xanthine oxidase and triglycerides in serum of patients with hyperlipoproteinemia, type IV. Biomed Biochim Acta. 1984;43(10):1201–3.PubMed

32.

Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila-Casado C, Vega-Campos IP, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294(4):F710–8. doi:10.1152/ajprenal.00454.2007.CrossRefPubMed

33.

Real JT, Martinez-Hervas S, Garcia-Garcia AB, Civera M, Pallardo FV, Ascaso JF, et al. Circulating mononuclear cells nuclear factor-kappa B activity, plasma xanthine oxidase, and low grade inflammatory markers in adult patients with familial hypercholesterolaemia. Eur J Clin Invest. 2010;40(2):89–94. doi:10.1111/j.1365-2362.2009.02218.x.CrossRefPubMed

34.

Saviola G, Benucci M, Abdi-Ali L, Sacco S, Cera I, Rossini M. Can febuxostat reduce triglyceride and cholesterol serum levels in gouty patients? J Clin Rheumatol. 2014;20(7):394–5. doi:10.1097/RHU.0000000000000168.PubMed

35.

Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials. 2014;15:26. doi:10.1186/1745-6215-15-26.PubMedCentralCrossRefPubMed

Title: Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial
Authors: Kenichi Tanaka
Masaaki Nakayama
Makoto Kanno
Hiroshi Kimura
Kimio Watanabe
Yoshihiro Tani
Yoshimitsu Hayashi
Koichi Asahi
Hiroyuki Terawaki
Tsuyoshi Watanabe
Publication date: 01-12-2015
Publisher: Springer Japan
Published in: Clinical and Experimental Nephrology / Issue 6/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-015-1095-1

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2015

Does lactate account for all of the increase in anion gap in cases of metformin-induced lactic acidosis?

A plain X-ray in peritoneal dialysis-related peritonitis

Serum uric acid and the incidence of CKD and hypertension

Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD)

Hypomagnesemia and atherogenic dyslipidemia in chronic kidney disease: surrogate markers for increased cardiovascular risk

Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page